Research Article

Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells

Figure 1

Improvement of the SLEDAI score during the 12 months following allogeneic BM/UC-MSC treatment (). During the year after allogeneic BM/UC-MSC injection, the SLEDAI score improved significantly () over time with median values of 9 (4–20), 8 (0-16), 6 (0-18), and 5 (0-18) at 1, 3, 6, and 12 months, respectively, as compared to baseline 13 (8-34).